Mitochondrial Myopathy Diagnosis & Treatment Market Research Report- Global Forecast till 2020

Report / Search Code: MRFR/Pharma/2648-CRR
Publish Date: June, 2017

Request Sample

Price
1-user PDF : $ 4450.0
Enterprise PDF : $ 6250.0

Description:

Mitochondrial Myopathy Diagnosis & Treatment Market Information: By Type (MELAS, PEO, MERRF, MNGIE, KSS, MDS, NARP) By Diagnostic Tests (genetic tests, muscle biopsy) By Therapy (Supportive Therapy, Targeted Therapy) - Global Forecast Till 2020

Market Scenario

Mitochondrial myopathies are associated with mitochondrial diseases which are caused by certain nuclear DNA deletions and mutations. Mitochondrial myopathies affect mitochondria which is responsible for energy production within a cell associated with mitochondrial disease. Thus, they cause low energy and free radical production which results in a variety of symptoms. The factors such as rising number of screening services for mitochondrial disorders, growing number of mitochondrial myopathy cases, increased government funding and incentives for rare genetic diseases are driving the market for mitochondrial myopathy diagnosis & treatment. However, poor treatment options and absence of curative treatment have constrained the market. Considering all these factors, the market for mitochondrial myopathy diagnosis & treatment is expected to reach $33.6 million by the end of 2020, this market is projected to growing at a CAGR of ~ 9.82% during 2017-2020.

Key Findings

Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) and Progressive External Ophthalmoplegia (PEO) are the most commonly found conditions in patients with mitochondrial myopathy. The global MELAS diagnosis & treatment market is expected to grow at the CAGR of 19.39% during 2017 to 2020. Genetic tests accounted for the largest market share in 2016, and is projected to grow at a CAGR of 10.11% during 2017 to 2020. Supportive therapy captured the whole market share in 2016, and is projected to grow at a CAGR of 9.82% during 2017 to 2020.

Research Methodology
**Research Methodology**

Sources: Genetic and Rare Diseases Information Center (GARD), Orphanet, The United Mitochondrial Disease Foundation (UMDF), World health Organization (WHO), Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation.

**Intended Audience**

Global Mitochondrial myopathy diagnosis & treatment solutions, manufacturers & suppliers
Research and development (R&D) companies
Hospitals and clinics
Academic institutes and universities

Figure 1 Global Mitochondrial myopathy diagnosis & treatment Market by Type, 2016 (% Market Share)

Segments:
The global mitochondrial myopathy diagnosis & treatment market is segmented on the basis of type, diagnostic tests and therapy. Based on type, the market has been segmented as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO), myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE), Kearns–Sayre syndrome (KSS), mitochondrial DNA depletion syndrome (MDS), Pearson syndrome, Leigh syndrome, neuropathy, ataxia, and retinitis pigmentosa (NARP). Based on the diagnostic tests, the market has been segmented as genetic tests, muscle biopsy and biochemical test. Based on the therapy, the market has been segmented as supportive therapy and targeted therapy.

Regional Analysis

The Americas account for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The Americas mitochondrial myopathy diagnosis & treatment market is expected to reach USD 116.7 million by the end of 2020 at the CAGR of 19.39% during 2017 to 2020. The faster market uptake of new technology in the US is also an important driver of the market for global mitochondrial myopathy diagnosis & treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Asia Pacific mitochondrial myopathy diagnosis & treatment market is expected to reach USD 4.4 million by the end of 2020 at the CAGR of 9.94% during 2017 to 2020. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.

Key players of Global Mitochondrial Myopathy Diagnosis & Treatment Market:

Key players profiled in the report are Centogene AG, GeneDx, Ixchel Pharma, Khondrion BV, Mitobridge, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., Stealth Biotherapeutics and others.

The report for Global Mitochondrial myopathy diagnosis & treatment Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.